A mouse glioblastoma cell line, termed GL261, was shown to express high levels of proteins involved in melanin biosynthesis such as the tyrosinase-related protein-2 (TRP-2), which is commonly overexpressed in melanoma cells. Mice injected with GL261 cells developed a CD8 + T-cell response to TRP-2 and a DNA vaccine expressing human (h)TRP-2 induced CD8 + T cells that recognized TRP-2 expressed by GL261 cells indicating that this melanoma-associated antigen may be suited for active immunotherapy of glioblastoma. Mice vaccinated with a DNA vaccine expressing TRP-2 were partially protected against subcutaneous, intravenous, or intracerebral challenge with the glioblastoma cells. Vaccine-induced protection against intracerebral challenge required both CD4 + and CD8 + T cells. Vaccine efficacy was enhanced upon addition of IL-12 as a genetic adjuvant. These results indicate that this well-defined melanoma-associated antigen can induce an adaptive immune response, which limits the intracerebral progression of a glioblastoma.
A ctive immunotherapy may be an attractive option for cancers that are poorly accessible, highly invasive into vital organs, and thus difficult to eliminate by surgical resection, such as glioblastoma, the most common form of primary intracranial malignancies. 1 Vaccines to cancer aim at inducing immune effector cells to tumor-specific or tumor-associated antigens. Many of the tumor vaccines that are currently being used in clinical trials are based on custom-made treatments such as autologous tumor cells transfected with cytokine-expressing vectors 2 or on the patients' dendritic cells (DCs) 3 pulsed ex vivo with tumor cell extract or tumor cell mRNA. These custom-made vaccines commonly express all of the proteins present in the tumor cells regardless of their ability to induce a tumor-specific immune response. Alternatively, subunit vaccines in which one or several well-defined tumor-associated antigens (TAAs) are incorporated into a vaccine carrier such as a DNA vaccine or a viral recombinant vaccine are being developed for clinical use. TAA-specific subunit vaccines have been tested extensively and with considerable success in preclinical melanoma models [4] [5] [6] [7] and are now in clinical trials. 8 The development of TAA-specific vaccines to melanoma was possible due to prior identification of a number of melanoma-associated antigens (MAAs) such as those belonging to the MAGE, BAGE and GAGE multigene family as well as the lineage-specific differentiation antigens gp100, tyrosinase (Tyr), and tyrosinaserelated proteins-1 and 2 (TRP-1 and TRP-2), respectively. In the wake of the human genome project, such TAAs are now rapidly being identified for a number of other types of cancer. During our attempt to develop a vaccine against glioblastoma based on DCs pulsed with the RNA of a mouse glioblastoma cell line, we consistently observed that vaccinated mice developed coat depigmentation suggesting induction of an immune response against proteins of the melanogenesis pathway. 9 This indicated shared antigens between melanoma and glioma cells, which is conceivable regarding their common embryonal origin from the neural ectoderm.
Here we show that a mouse glioblastoma cell line, termed GL261, expresses high levels of several MAAs. One of these antigens, that is, TRP-2, expressed by a DNA vaccine induces protective T-cell-mediated immunity to a subsequent peripheral or intracerebral challenge with an otherwise fatal dose of GL261 tumor cells.
Materials and methods

Mice
C57Bl/6 mice, knockout (KO) mice for beta-2 microglobulin (2-KO, B6.129P2-B2m tm1unc ), perforin (perforin-KO), and CD4 (CD4-KO, B6.129S2-Cd4 tm1Mak ) were purchased at 6 weeks of age from Jackson Laboratories (Bar Harbor, ME). Knockout mice for p53 (p53KO) and IL-4 (IL-4KO) were bred at The Wistar Institute's Animal Facility.
Reagents
Growth-factor-reduced Matrigel
s is a soluble basement membrane extract from Engelbroth-Holm-Swarm mouse tumors that gels to form basement membranes. 10, 11 Matrigel composed mainly of laminin, collagen IV, entacin, and heparin sulfate protoglycan was purchased from Collaborative Biomedical Products (Bedford, MA). The nonamer peptide corresponding to amino acids 180-188 SVYDFFVWL, which carries the immunodominant epitope of human or mouse TRP-2 for mice of the H-2 b haplotype, 12 was synthesized and sequence-verified by mass spectrophotometry at the Peptide Facility of the Wistar Institute.
Plasmids
The plasmid expressing human TRP-2 (hTRP-2) under cytomegalovirus promoter/enhancer, pRcCMV-hTRP-2, was a gift of Dr Shigeki Shibahara, Tohoku University School of Medicine (Sendai, Japan). 13 The plasmid, expressing mouse TRP-2 (mTRP-2), was constructed as follows: RNA was isolated from B16F10 melanoma cells and reverse transcribed. The cDNA was amplified by polymerase chain reaction using terminal primers for the mTRP-2 sequence. The amplicon was cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) and the insert was sequenced. The insert was excised by digestion with EcoRV and HindIII and cloned into the corresponding sites of the pcDNA3 vector resulting in pcDNA3mTRP-2. Empty pRcCMV and pcDNA3 vectors were used as controls for the in vivo protection experiments. The pIL-12 vector, pWRG-3169 mIL12, is a bicistronic plasmid containing the sequences for the p35 subunit, an internal ribosomal entry site, followed by sequences encoding the p40 subunit.
Cell lines
GL261 cells are derived from a chemically induced glioblastoma of C57Bl/6 mice and have been described previously.
9 B16F10 melanoma cells of a C57Bl/6 background were obtained from the American Type Culture Collection, Bethesda, MD. The (ff)1 cell line is an embryonic immortal fibroblast line that was derived from a homozygote p53KO embryo. Tumor cells as well as TAP-deficient RMAS cells and monkey kidney (COS-7) cells were cultured in vitro in Dulbecco's modified Eagles medium (DMEM) (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, and antibiotics.
Transient transfection of cells
(ff)1 cells were plated at 2 Â 10 5 cells in six-well plates. The next day cells were washed with serum-free DMEM and transfected for 4 hours with 1 mg/well of plasmid vector in 1 ml of serum-free medium. The vector had been precipitated with Effectin (Qiagen, Valencia, CA) according to the manufacturer's instructions. Cells were then cultured for an additional 44 hours in DMEM with FBS and antibiotics.
Immunoprecipitation
The expression of TRP-2 protein was demonstrated in GL261 cells and B16F10 cells using (ff)1 cells as control. Cells were metabolically labeled with 35 S-methionine and processed for immunoprecipitation. Expression of the TRP-2 protein was detected by a specific rabbit antiserum developed against the C-terminal peptide of TRP-2, which was kindly provided by Vincent Hearing (NIH, Bethesda, MD). Following antibody binding and precipitation with Sepharose G, the supernatants were processed with the Laemmli sample buffer (Bio-Rad, Hercules, CA) and run on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Finally, gels were dried and exposed on Reflectiont film (NENt, Life Sciences Products, Boston, MA).
Quantitative reverse transcription polymerase chain reaction (RT-PCR)
Expression of transcripts for MAAs in B16F10 cells, GL261 glioblastoma cells, and cells from normal C57Bl/6 mouse brain was quantitated by a real-time RT-PCR as described 14 
Immunization and challenge of mice
Mice were immunized against tumor cells by injecting 2 Â 10 6 irradiated (10,000 rad) tumor cells subcutaneously (s.c.). Mice were immunized intramuscularly (i.m.) with 50-100 mg of DNA in 100 ml of PBS given at equal doses into both quadriceps muscles. Prior to injection into mice, tumor cells were harvested, washed three times in DMEM, and suspended in PBS. Mice were inoculated s.c. or intracranially (i.c.) with graded numbers of GL261 cells to establish the minimal tumorigenic dose (TD 100 ), defined as the number of cells that causes palpable (s.c.) or symptomatic (i.c.) tumors in 100% of control mice within 2-4 weeks. The TD 100 for s.c. and i.c. inoculation was shown to be 1. 
Isolation of lymphocytes
Matrigel-tumors were harvested from euthanized mice as follows. The skin section to which the matrigel adhered lightly was excised. The gel was peeled off and placed into a Petri dish onto a stainless-steel grid. DMEM (5 ml) was added and the gel was disintegrated using tweezers and by rubbing small pieces against the mesh to release the entrapped lymphocytes. Cells were filtered through a nylon mesh, washed three times with serum-free medium, and then used for further analysis. Live tumor cells, which adhere more firmly to the matrigel, were not recovered by this procedure. Splenocytes were prepared by routine procedures for further analysis.
Analysis of T-cell responses
51
Cr-release assay. Cell-mediated cytolysis was tested with a standard 51 Cr-release assay. Splenocytes obtained from naı¨ve mice or DNA immunized mice were prepared 1 week after the last immunization. Splenocytes from mice immunized with irradiated GL261 were harvested 2 weeks following immunization. A total of 5 Â 10 6 splenocytes were stimulated with 2 mg/ml of peptide corresponding to amino acids 180-188 of TRP-2 (SVYDFFVWL 12 ), which carries the immunodominant epitope of TRP-2 in 1.6 ml of DMEM supplemented with 2% FBS and 10 À6 M of 2-mercaptoethanol. Following 5 days in culture, splenocytes were collected and cocultured with 51 Cr-labeled target cells in 96-V-bottom well microtiter plates (Nunclon, Nunc, Roskilde, Denmark) in 200 ml of DMEM supplemented with 10% FBS at various effector:target (E:T) cell ratios. GL261 glioma, B16F10 melanoma, untreated RMAS cells, or RMAS cells that had been pulsed overnight at room temperature with 10 mg of peptide per ml (10 6 cells in 2 ml of serum-free medium) were used as target cells (5 Â 10 3 cells/well). Cold-target cell inhibition experiments were performed by adding a 10-or 50-fold excess of unlabeled GL261 cells per reaction. Supernatant was harvested 5 hours later and counted in a gamma-counter. % Specific lysis was calculated using the formula experimental 51 Cr-release-spontaneous release maximal 51 Cr-release-spontaneous release Â 100
Data are presented as mean of triplicate 7SD.
Intracellular cytokine staining
Lymphocytes (1 Â 10 6 /well in 96-well microtiter plate) were stimulated with the TRP-2 peptide amino acids 180-188 (10 mg/ml) and 100 U/ml of IL-2 in the presence of 1 ml/ml of Brefeldin A for 5 hours in 200 ml of medium in v-bottom microtiter plate wells. Cells cultured without the peptide were used as controls. After 5-hour incubation at 371C, cells were treated for 45 minutes on ice with 25 ml of a 1:100 dilution of FITC-labeled antibody to CD8. Cells were washed and then permeabilized with Cytofix (Pharmingen, San Diego, CA), and treated for 45 min on ice with a phytoerythrin (PE)-labeled antibody to mouse interferon (IFN)-g. Cells were washed and analyzed by the Flow Cytometry Core Facility of the Wistar Institute on an EPICS XL flow cytometer (Coulter Corp., Hiatech., FL). Data were analyzed with the WinMDI software, version 2.8.
Results
Glioblastoma cells express MAAs
Since both melanocytes and glial cells are derived embryologically from the neural ectoderm, we hypothesized that melanoma and glioma cells may share common antigens. This hypothesis was originally supported by the observation that mice immunized with GL261 RNAtransfected DCs developed visible coat depigmentation indicative of a disruption of the melanin pathway upon immunization. [15] [16] [17] Using a quantitative RT-PCR, we compared levels of mRNA expression of five MAAs, that is, Tyr, TRP-1, TRP-2, gp100, and murine homolog of human MAGE-1 (Smage2), in GL261 cells, B16F10 melanoma cells, and normal mouse brain tissue. As shown in Fig 1, GL261 glioma cells express transcripts for all of the MAAs under interrogation, that is, Tyr, TRP-1, TRP-2, gp100, and Smage2, at a higher level than cells from normal brain. TRP-2 RNA levels were higher in GL261 than in B16F10 cells, while the other transcripts were more abundant in the melanoma cell line. Transcripts for gp100 could be detected in normal brain but were at higher levels in either of the tumor cell lines. Expression of TRP-2 protein, one of the TAAs that had been used successfully for active immunotherapy of melanoma, [15] [16] [17] in GL261 and B16F10 cells was further confirmed by immunoprecipitation followed by gel electrophoresis (not shown).
TRP-2 as expressed by GL261 cells provides a target for CD8 + T cells
We initially determined if immunization with GL261 tumor cells induces an immune response to TRP-2. For these experiments, we used a technique that was recently developed in our laboratory. 10 This technique is based on matrigel, a mixture of cellular matrix proteins derived from a mouse tumor cell line, which is in a liquid form at low temperatures but solidifies into a firm gel at body temperature. Tumor cells mixed with matrigel are retained within the gel upon inoculation into animals. Matrigels containing tumor cells become vascularized and recruit a cellular infiltrate, which over time in vaccinated mice becomes highly enriched for T cells specific for antigens expressed by the tumor cells. The infiltrating cells can be easily recovered from the matrigel-tumors and then analyzed by functional assays or by flow cytometry. Naı¨ve C57BL/6 mice were injected with 2 Â 10 6 GL261 cells incorporated into matrigel. After 1 week, matrigels were recovered and lymphocytes were isolated. Approximately 8.6% of all CD8 + T cells recovered from the GL261 cell-matrigels responded to the TRP-2 peptide by synthesis of IFN-g (Fig 2c) as compared to 2.8% of cells that spontaneously secreted IFN-g without in vitro stimulation (Fig 2b) . These results suggest that the GL261 cells induced CD8 + T cells to TRP-2 in vivo. This was further confirmed by testing splenocytes from GL261 or B16F10 cell-immunized mice for lysis of TRP-2 peptide expressing target cells. Both populations of splenocytes upon a 5-day in vitro expansion with the TRP-2 peptide specifically lysed TRP-2 peptide-coated RMAS cells. Splenocytes from GL261-immune mice exhibited markedly higher lytic activity compared to those from B16F10-immune mice (Fig 3) .
Genetic immunization with cDNA encoding hTRP-2 induces a CD8 + T-cell response
To confirm that TRP-2 serves as a TAA in the GL261 cell line, a DNA vaccine expressing the human form of TRP-2 was tested for induction of a transgene product specific CD8 + T-cell response in C57Bl/6 mice. We chose the human rather than the murine homolog of TRP-2, which both share the same immunodominant T-cell epitope, assuming that the presence of sequence differences unrelated to the CD8 epitope may facilitate induction of a CD8 + T-cell response by providing additional epitopes to T helper cells. The plasmid pRcCMV-hTRP-2 13 was injected at 50 mg i.m. three times in 2-week intervals into groups of C57Bl/6 mice. Mice developed coat depigmentation, which was first noted 2-3 weeks after the second immunization, and which intensified after the third immunization. At 2 weeks after the third immunization, splenocytes were isolated and cultured for 5 days with the TRP-2 peptide. Effector cells were tested for lysis of unmodified or TRP-2 peptide-pulsed RMAS cells or GL261 cells. Owing to a defect in the peptide transporter TAP, RMAS cells do not carry stable major histocompatibility complex (MHC) class I determinants on their cell surface. Treatment of RMAS cells with peptides that bind to their MHC class I molecules stabilizes their expression on the cell surface where they can then be recognized very efficiently by CD8 + T cells, which recognize the peptide-MHC complex. As shown in Fig 4, splenocytes from naı¨ve mice failed to lyse TRP-2-coated RMAS cells or the GL261 cell line, which were both lysed by splenocytes from TRP-2-immune mice. To ensure that GL261 cells were killed due to recognition of the TRP-2 epitopes, radiolabeled TRP-2 peptide-pulsed RMAS cells were incubated with the effector cells in the presence of a 10-to 50-fold excess of cold, that is unlabeled, GL261 cells. Addition of GL261 cells inhibited lysis of TRP-2-coated RMAS cells. These data indicate that the DNA vaccineactivated CD8 + T cells from TRP-2-DNA immunized mice specifically lyse TRP-2-expressing target cells including GL261 glioblastoma cells.
DNA vaccine encoding hTRP-2 induces protection against tumor challenge
We next tested if mice immunized with the DNA vaccine to TRP-2 were rendered resistant to peripheral, that is s.c., challenge with GL261 cells. Mice were immunized three times with the DNA vaccine expressing either human or mouse TRP-2, as described above. The DNA vaccine was either given alone or mixed with 50 mg of a plasmid vector encoding both chains of mouse IL-12.
18
Control mice were injected with an empty pcDNA3 vector combined with the cytokine-expressing vector. Groups of 6-8 mice were then challenged with 1.5 Â 10 5 GL261 glioma cells s.c. and tumor growth was measured twice weekly. Fig 5 shows a representative experiment . Approximately, 20% of mice immunized with the control vector or the vector encoding IL-12 remained tumor free upon injection of a dose of GL261 cells that causes progressive tumor growth in untreated mice. This low level of protection, which we have observed in other tumor models, 19 presumably reflects the effects of bacterial DNA containing unmethylated CpG motifs 20 that interact with the Toll-like receptor 9 on cells of the innate immune system 21 resulting in the production of proinflammatory cytokines. None of the mice vaccinated with the DNA vaccine to mTRP-2 remained disease-free (not shown), while approximately 40% of mice immunized with the vector encoding hTRP-2 were completely protected against the development of a clinically apparent tumor (Fig 5a) . The level of protection was increased to B70% upon addition of the vector encoding IL-12, as shown previously with an experimental DNA vaccine to melanoma (Fig 5b) . 22 In the next set of experiments, groups of vaccinated mice were challenged i.v. with 1 Â 10 5 B16F10 melanoma cells, which results in heavily pigmented lung metastases in naı¨ve mice or with 1 Â 10 5 GL261 cells. The number of macroscopically visible metastases on the surface of the 
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InSug O et al lungs was counted under a dissecting microscope 21 days after challenge. In a series of experiments it was established that 60% of DNA-immunized mice were protected against i.v. challenge with B16F10 cells, while on average over 80% were completely protected against i.v. challenge with the GL261 cell line (Fig 6a) . Most of the remaining mice showed a reduction in the number of lung tumors as shown in Fig 6b. Fig 6c shows the number of lung tumors per mouse for one of the experiments. These results demonstrate that a vaccine-induced immune response to TRP-2 provides partial protection in an experimental metastatic model for glioblastoma or melanoma cells.
To mimic human glioblastoma, mice vaccinated with the vector encoding human or mouse TRP-2 with or without the vector encoding IL-12 were next challenged with GL261 cells directly injected into the central nervous system. Mice were euthanized once they developed symptoms indicative of a cerebral disease. Brains were recovered after euthanasia to ensure presence of a macroscopically visible tumor. Mice that remained disease free were observed for at least 55 days. As shown in Fig 7, vectors expressing human or mouse TRP-2 provided complete protection to 60 and 30% of GL261-challenged mice, respectively. The construct encoding the human version of TRP-2 also affected a delay in onset of symptoms, which was not observed in mice vaccinated with the vector encoding mTRP-2, suggesting that the former was more efficacious at inducing an immune response against the tumor as had been observed in the s.c. challenge model. Efficacy of the hTRP-2 vaccine was enhanced by the addition of the vector for mouse IL-12 (Fig 7) . As seen upon subcutaneous challenge, a low percentage of mice vaccinated with the control vectors resisted the development of intracranial tumors, which we again attribute to activation of cells of the innate immune system by the unmethylated CpG motifs of the vectors.
Vaccine-induced protection against GL261 cell challenge requires both CD4 + and CD8 + T cells
The immune effector mechanisms that provide protection against intracerebral GL261 cell challenge were investigated further in KO mice. As shown in Fig 8, lack of Mice were euthanized once they developed symptoms indicative for a CNS disease. Mice were scored as protected if they remained diseasefree for 55 days. 
Discussion
Although DNA vaccines have thus far performed poorly in clinical trials, [23] [24] [25] their efficacy in preclinical small rodent models against infectious diseases or cancers has been impressive. 26 ,27,4-6 DNA vaccines are easy to construct and they induce a full spectrum of immune responses including CD8 + T cells, 26 which have been implicated to play a major role in tumor cell eradication. DNA vaccines unlike many of the traditional vaccine carriers induce T cells to subdominant epitopes of the transgene product. 28 This may make them highly suited for immunotherapy of cancers that commonly carry TAAs in the form of aberrantly expressed self-proteins to which T cells to the immunodominant epitopes have been deleted or anergized. DNA vaccines due to unmethylated CpG motifs present in the bacterial part of the vector, which interact with TLR-9 causing activation of the NFkB pathway 21 if given at high doses i.m., induce a Th1 type immune response best suited to elicit CD8 + T cells. Thus, although DNA vaccines commonly induce less potent immune responses compared to other recombinant vaccine carriers, such as E1-deleted adenoviral recombinants, 29 they could be highly suited to screen TAAs for the induction of antitumor immune responses in pre-clinical small animal models.
Owing to a previous observation that mice vaccinated with dendritic cells pulsed with the RNA of the GL261 glioblastoma cell line develop fur depigmentation, 9 we tested GL261 cells for the expression of a number of antigens involved in melanin synthesis. All of the antigens tested, with the exception of gp100, were expressed by the glioma cell line, but not in normal brain, suggesting that vaccines expressing melanoma-associated antigens may be suited for immunotherapy of glioblastoma. TAA expression in melanoma has been exceptionally well characterized, which has facilitated the preclinical and clinical development of vaccines to this cancer. TAAs of glioblastoma, a cancer that is less common than melanoma and that cannot as easily be diagnosed at its early stages of development, are less well characterized, which has hampered the development of active immunotherapy for this type of cancer. The observation that several of the well-defined melanoma-associated antigens are expressed in glioblastoma led us to test if they may also serve to elicit adaptive immune responses to glioblastoma. We selected the TRP-2 antigen for these preclinical studies for several reasons. (1) TRP-2 is not expressed in brain cells of healthy mice, which lessens the risk of vaccine-induced autoimmune responses within the central nervous system (CNS). (2) Transcripts for TRP-2 were shown to be as abundant in the glioblastoma cell line as in the B16F10 mouse melanoma cells. (3) Previous studies had shown that mice vaccinated to TRP-2 became partially resistant to challenge with the B16F10 melanoma cells [6] [7] [8] 16 demonstrating that this antigen is suited to induce an efficacious antitumor immune response to an otherwise highly aggressive transplantable tumor. Human melanoma patients spontaneously develop antibodies to TRP-2 30 and upon vaccination with a polyvalent vaccine can generate CD8 + T-cell responses to this antigen. 31 (4) The immunodominant epitope of TRP-2 has been identified in mice of the H-2 b haplotype such as C57Bl/ 6 mice, 12 which facilitates testing of immune correlates of protection. In addition, mouse and human TRP-2 show extensive sequence homology and the immunodominant epitope is conserved in both sequences and it is identical for mice of the H-2 b haplotype and humans carrying the HLA-A*0201 allele. (5) Our initial studies demonstrated that mice injected with GL261 cells developed a CD8 + Tcell response to the immunodominant epitope of TRP-2.
The DNA vaccines expressing hTRP-2 induced a CD8 + T-cell response and protection to challenge with GL261 cells given through three different routes. Some protection against an s.c. challenge with a fairly high dose of GL261 cells could be demonstrated. Nevertheless, the percentage of vaccinated animals that remained disease free was not overly impressive unless the hTRP-2 vaccine was administered concomitantly with a vector expressing both chains of mouse IL-12. A previous study using bioballistic DNA vaccination demonstrated increased efficacy of a DNA vaccine to TRP-2 codelivered with a vector encoding IL-12 in a B16F10 melanoma challenge model. 4 IL-12 is a pleiotropic cytokine that is mainly produced by cells of the innate immune systems as well as by B cells. Heterodimers of the two chains of IL-12, that is, p35 and p40, induce production of immune interferon and cause activation of natural killer cells. IL-12 promotes the development of Th1 type immune responses while inhibiting polarization of immune responses toward the Th2 pathway. IL-12, in addition through the induction of IFN-g, which in turn promotes synthesis of MIG and IP-10, has antiangiogenic activity. 32 Which one of these mechanisms of IL-12 increased the efficacy of the DNA vaccine to TRP-2 is currently unknown. Vaccineinduced protection was more pronounced against a lower dose tumor cell challenge given i. Most importantly, the DNA vaccine to hTRP-2 especially if given together with an IL-12-encoding vector induced protective immunity to challenge with GL261 cells inoculated directly into the CNS. In this model, the DNA vaccine to mTRP-2 induced some protection unlike in the s.c. challenge model. The hTRP-2-expressing DNA vaccine was more efficacious. We assume that the xenogeneic protein may induce better protective immunity by providing additional epitopes able to promote a CD4 + T helper cell response, which would be expected to increase the CD8 + T-cell response to the immunodominant epitope shared between mouse and human TRP-2. To what degree additional T help is needed might in part relate to the method of immunization as well as the DNA vaccine carrier, which influences induction of the innate immune response through CpG motifs of the bacterial part of the vector as well as the magnitude of the adaptive immune response by determining antigenic load. This could explain why in some mouse tumor systems, DNA vaccines encoding mouse TRP-2 induced protection against mouse melanoma cells, 6 while in our glioblastoma model DNA vaccines expressing mTRP-2 performed less well than those expressing hTRP-2.
The mechanisms limiting immune responses within the confines of the brain remain poorly understood. The central nervous system is an immunologically privileged site that protects irreplaceable neurons from potentially destructive immune effector mechanisms. To this end, it is guarded by the blood-brain barrier that is impermeable for resting lymphocytes or large effector molecules, such as antibodies. 33 Furthermore, neurons fail to express MHC class I or II determinants and thus provide neither a stimulus nor a target for T cells. 34 Microglial cells and astrocytes can express antigen in the context of MHC class I and II molecules, but their function in antigen presentation is ill defined. 35 The brain lacks a lymphatic surveillance system such as lymph nodes where T cells become activated. 36 Furthermore, glioblastoma cells can subvert immune responses. 37 For example, some glioblastoma cells express Fas ligand, which can cause the demise of fas-expressing T effector cells. 38 Glioblastoma cells can secrete both the latent and active form of transforming growth factor-, 39, 40 a cytokine that inhibits proliferation of T cells and the effector functions of cytolytic T cells 41, 42 and may thus contribute to the local suppression of immune functions within the CNS. 43 Glioma cells also secrete prostaglandin E2, which inhibits production of cytokines such as IFN-g and chemokines. 44, 45 Secretion of interleukin 10 (IL-10), a Th2 type cytokine, correlates with a poor prognosis for human astrocytic tumors. 46 IL-10 downregulates expression of MHC class II determinants by monocytes and inhibits IFN-g and TNF-a production. 47, 48 It also drives immune responses toward the Th2 pathway and prevents stimulation of Th1 type immune responses needed for activation of cytolytic T cells. Nonetheless, activated immune cells can invade the CNS as documented in autoimmune diseases such as multiple sclerosis in humans or experimental allergic encephalitis in rodents. [49] [50] [51] Peripheral immunization with myelin basic protein elicits antigen-specific T-cellmediated CNS demyelination suggesting that T cells activated in the periphery can cross the blood-brain barrier and commence effector functions once they encounter their specific antigen in the brain. These results are further supported by recent observations that effective anti-CNS tumor immune responses can be generated through the use of cytokine-gene-modified tumor cell vaccines or dendritic cell vaccines. 9, 52, 53 The mechanisms that provide protection against intracerebral challenge tested in KO mice of the C57Bl/ 6 background were found to be complex. A significant percentage of mice vaccinated with the control vaccine were shown to be resistant to tumor cell challenge given either s.c. or i.c. This spontaneous resistance in TRP-2 naı¨ve mice was mediated mainly by T cells, as tumors progressed more rapidly in sham-vaccinated CD4KO and b2KO mice and none of the mice survived the challenge. We assume that in wild-type mice, the tumor cells may have elicited an adaptive immune response, which in concert with innate immune mechanisms triggered by the empty DNA vectors halted tumor progression. This was unexpected as tumor cells growing within the confines of the CNS are not expected to induce an adaptive immune response. Injection of the tumor cells in this artificial tumor transplantation model physically disrupts the blood-brain barrier and causes local injury, which results in an inflammatory reaction that we described previously. 9 This injury may facilitate recruitment and activation of cells of the innate immune system needed to present antigen to naı¨ve T cells. Tumor cell eradication in sham-vaccinated mice relied on perforin, although this mediator seemed to affect a later stage of tumor rejection, as the kinetics of tumor development was delayed in perforin KO mice compared to CD4KO or 2KO mice. Upon vaccination, both CD4 + and CD8 + T cells were needed to affect tumor rejection as has been shown previously with a DNA vaccine to TRP-2 used against a mouse melanoma cell line. Whether CD4 + T cells exhibited crucial effector functions against the tumor cells or were needed to sponsor optimal activation and expansion of CD8 + T cell to TRP-2 was not investigated. IL-4 was also required, which was unexpected considering the propensity of DNA vaccines to elicit Th1 type immune responses and the beneficial effect of the addition of IL-12, a Th1 cytokine, on vaccine efficacy.
In summary, we have shown here in a preclinical rodent model that a vaccine expressing the melanoma-associated TRP-2 antigen induces a T-cell-mediated response that provides protection to intracranial challenge with a syngeneic glioblastoma cell line. Overexpression of mRNA for additional MAAs was demonstrated in the mouse glioblastoma cell line indicating that a multivalent vaccine to glioblastoma based on several of the welldefined MAAs, which would be anticipated to show increased efficacy by its ability to elicit a broader T-cell response, could be generated. Although additional studies are needed to confirm that human glioblastoma cells express melanoma-associated antigens, our data provide the basis for the development of a novel immunotherapy option for glioblastoma.
